What question did this study set out to answer?

The research aims to identify Candida species from clinical samples and evaluate their virulence and antifungal resistance.

February 12, 2026AntibioticsOpen Access

Molecular Identification, Virulence Factors, and Antifungal Susceptibility Profiles of Candida Isolates from Clinical Samples of Intensive Care Patients

View Full Paper

Ask AI

Bookmark

The research aims to identify Candida species from clinical samples and evaluate their virulence and antifungal resistance.
Included 100 Candida isolates from intensive care unit patients.
Used standard microbiological and molecular methods for species identification.
Assessed virulence factors through assays for protease, phospholipase, hemolysis, and biofilm activity.
Employed EUCAST liquid microdilution to evaluate antifungal susceptibility.
Identified 39 isolates as Candida albicans and 61 as non-albicans species.
Species identification accuracy was 71% for Chromagar Candida and 87% for MALDI-TOF MS.
Protease activity was positive in 52%, phospholipase in 42%, hemolytic activity in 77%, and biofilm formation in 48%.
No significant MIC differences for antifungals among species, but trends showed C. albicans with higher fluconazole MICs.

No takes yet. Share an insight, caveat, or question.

Identifies Candida species and their virulence factors in ICU patients, suggesting essential insights for effective treatments.

Çelik et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark